Loading...
XTAE
DNA
Market cap35mUSD
May 13, Last price  
103.10ILS
1D
4.46%
1Q
-3.37%
Jan 2017
-51.18%
IPO
-96.26%
Name

DNA Group TR Ltd

Chart & Performance

D1W1MN
XTAE:DNA chart
No data to show
P/E
574.68
P/S
41,497.41
EPS
0.18
Div Yield, %
—
Shrs. gr., 5y
38.01%
Rev. gr., 5y
%
Revenues
306k
0.00%
000000000560,000306,000306,000
Net income
22m
P
-1,831,000-72,275,000-17,535,000-5,932,000147,356,000-14,287,000-38,534,000-19,265,00018,374,000-23,536,000-1,177,00022,096,000
CFO
2m
P
-5,346,000-11,141,000-15,635,000-14,321,000-1,905,000-1,661,000-1,373,000-611,000-2,331,000-354,000-678,0001,610,000

Profile

Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physicians, nurses, and operators in hospitals and clinics, as well as in pharmacies and other places. In addition, it engages in the development of oral drugs. The company was formerly known as D.N.A Biomedical Solutions Ltd. and changed its name to Dna Group (T.R.) Ltd in November 2022. Dna Group (T.R.) Ltd was incorporated in 2004 and is based in Tel Aviv-Yafo, Israel.
URL
IPO date
May 13, 2007
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
306
0.00%
306
-45.36%
560
 
Cost of revenue
885
1,093
1,228
Unusual Expense (Income)
NOPBT
(579)
(787)
(668)
NOPBT Margin
Operating Taxes
1,307
38,269
Tax Rate
NOPAT
(1,886)
(787)
(38,937)
Net income
22,096
-1,977.32%
(1,177)
-95.00%
(23,536)
-228.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
41,051
BB yield
-48.37%
Debt
Debt current
Long-term debt
Deferred revenue
480
786
1,093
Other long-term liabilities
Net debt
(68,311)
(66,698)
(81,786)
Cash flow
Cash from operating activities
1,610
(678)
(354)
CAPEX
Cash from investing activities
1,296
854
Cash from financing activities
41,051
FCF
(1,886)
(787)
(38,937)
Balance
Cash
68,311
66,698
65,729
Long term investments
16,057
Excess cash
68,296
66,683
81,758
Stockholders' equity
89,979
214,628
80,106
Invested Capital
33,649
13,290
1,093
ROIC
ROCE
EV
Common stock shares outstanding
123,164
116,574
Price
0.87
38.29%
0.63
-13.19%
0.73
-53.84%
Market cap
77,840
-8.28%
84,866
-39.00%
EV
73,046
64,065
EBITDA
(579)
(787)
(668)
EV/EBITDA
Interest
Interest/NOPBT